Should We Be Bullish on Ambev?

The best investors are not afraid to go against the grain. And buying shares in Ambev, which has an average analyst rating of only hold, would certainly fit the bill. Might patient investors be able to find value in this stock? Let's dive into numbers and see for ourselves.

Over the last year, Ambev shares have moved -7.8% while trading between the prices of $2.42 and $3.32. This represents a None% difference compared to the S&P 500, which moved None% over the last 52 weeks.

At its current price of $2.88 per share, ABEV has a trailing price to earnings (P/E) ratio of 19.2 based on its 12 month trailing earnings per share of $0.15. Considering its future earnings estimates of $None per share, the stock's forward P/E ratio is 19.2. In comparison, the average P/E ratio of the Consumer Defensive sector is 24.21 and the average P/E ratio of the S&P 500 is 15.97.

Ambev's P/E ratio tells us how much investors are willing to pay for each dollar of the company's earnings. The problem with this metric is that it doesn't take into account the expected growth in earnings of the stock. We can solve this problem by dividing the trailing P/E ratio by the company's five year earnings growth estimate, which in this case gives us a 2.07 Price to Earnings Growth (PEG) ratio.

A PEG ratio between 0 and 1 indicates a potentially undervalued stock. This metric is useful because some companies have a low P/E ratio for a reason: there is no earnings growth potential in the stock. Other companies may have high P/E ratios, but may still be undervalued if they have very high expected earnings growth rates. The main caveat with the PEG ratio is that it relies on the company's earnings growth estimates, which are potentially subject to manipulation.

We can also compare the ratio of Ambev's price to its book value. A company's book value refers to its present liquidation value: what would be left if the company sold off all its assets and paid off all of its debts today. Importantly, the book value does not include intangible assets such as the value of its brand and the goodwill (if any) of its customers. ABEV has a book value of 0.5, with anything close or below one indicating a potentially undervalued company.

A comparison of the share price versus company earnings and book value should be balanced by an analysis of the company's ability to pay its liabilities. One popular metric is the Quick Ratio, or Acid Test, which is the company's current assets minus its inventory and prepaid expenses divided by its current liabilities. Ambev's quick ratio is 0.776. Generally speaking, a quick ratio above 1 signifies that the company is able to meet its liabilities.

The final element of our analysis will touch on Ambev's capacity to generate cash for the benefit of its shareholders or for reinvesting in the business. For this, we look at the company's levered free cash flow, which is the sum of all incoming and outgoing cash flows, including the servicing of current debt and liabilities. Ambev has a free cash flow of $15,223,838,000.00, which it uses to pay its shareholders a 0.0381% dividend.

By most metrics, Ambev is an undervalued stock. So why are analysts giving it a low rating? It probably has to do with their perception of its limited growth potential, as represented by its elevated PEG ratio. For growth-oriented investors, ABEV is cheap for a reason. On the other hand, diehard value investors believe that if you wait long enough an undervalued stock will always reach a fair valuation. We will continue to monitor the stock to see which thesis prevails. Don't want to miss our next analysis? Make sure to subscribe to our free daily newsletter!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.